Protalix BioTherapeutics (NYSE:PLX) Shares Up 1.7%

Protalix BioTherapeutics, Inc. (NYSE:PLX)’s share price rose 1.7% on Tuesday . The company traded as high as $1.24 and last traded at $1.20. Approximately 272,095 shares changed hands during mid-day trading, a decline of 18% from the average daily volume of 330,242 shares. The stock had previously closed at $1.18.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of Protalix BioTherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, March 15th.

Protalix BioTherapeutics Price Performance

The stock’s 50 day moving average price is $1.35 and its two-hundred day moving average price is $1.49. The firm has a market capitalization of $87.66 million, a price-to-earnings ratio of 24.00 and a beta of 0.89.

Protalix BioTherapeutics (NYSE:PLX) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.04). Protalix BioTherapeutics had a return on equity of 29.73% and a net margin of 12.69%. The firm had revenue of $10.49 million during the quarter, compared to analyst estimates of $8.15 million. As a group, equities research analysts anticipate that Protalix BioTherapeutics, Inc. will post 0.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Protalix BioTherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC increased its position in Protalix BioTherapeutics by 561.5% during the second quarter. Barclays PLC now owns 13,230 shares of the company’s stock worth $26,000 after acquiring an additional 11,230 shares during the period. SG Americas Securities LLC bought a new position in Protalix BioTherapeutics during the third quarter worth $50,000. Bailard Inc. bought a new position in Protalix BioTherapeutics during the fourth quarter worth $121,000. Allspring Global Investments Holdings LLC bought a new stake in Protalix BioTherapeutics in the 3rd quarter valued at $229,000. Finally, Bank of New York Mellon Corp increased its holdings in Protalix BioTherapeutics by 12.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 165,680 shares of the company’s stock valued at $275,000 after buying an additional 18,760 shares during the period. Institutional investors own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.